Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
I just bought this pharma stock for its next generation of blockbuster drugs - and its dividend
We just initiated a new position in AbbVie Inc. at around $280 a share for our Enhanced Dividend Income Portfolio. While the dividend is certainly part of the appeal, I'm really into the company's next chapter of growth. The North Chicago-based…
Piramal Pharma Limited Announces Results for Q2 and H1 FY27
MUMBAI, India, Oct. 27, 2026 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half…
Mankind Pharma Reports 38% Profit Growth as Exports Lead Segment Gains
India-based Mankind Pharma's consolidated profit after tax rose 37.7% in the quarter ended Sept. 30, as exports led its business segments and consumer healthcare revenue barely moved. After-tax earnings on a consolidated basis totaled…
Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals
BEIJING, Oct 27 (Reuters) – Jiangsu Hengrui Pharmaceuticals, China's biggest drugmaker by market value, reported on Tuesday a rise of 88.9% in profit for the third quarter of 2026, driven by income from out-licensing deals. •…
Is govt allowing pharma companies to overprice medicines? SC flags massive gap in MRP and retailer cost
The Supreme Court on Tuesday slammed the Centre over the massive difference between the MRP of medicines and their purchase price for retailers, questioning who is monitoring drug prices in the country. A bench of Justices Vikram Nath and Sandeep…
Piramal Pharma Q2 results: Company swings to ₹5 crore profit
Piramal Pharma on Thursday reported a consolidated net profit of Rs 5 crore in the July-September period of the current fiscal year. The pharma company had posted a loss of Rs 99.22 crore in the year-ago period, the company said in a regulatory…
Astellas Bets Up to $1.3 Billion on Cancer Drug Yet to Enter Human Trials
Astellas Pharma Inc. agreed to pay as much as $1.34 billion for rights to an experimental cancer treatment from Melbourne-based Audax Biosciences that has yet to be tested in humans. Audax will receive an upfront payment and potentially another…
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 2.9% - Here's Why
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report)'s stock price rose 2.9% during trading on Monday. The company traded as high as $1.44 and last traded at $1.44. Approximately 16,654 shares traded hands during trading, a decline of…
Ascendis Pharma A/S (NASDAQ:ASND) Stock Moved Up to 'Hold' by Canaccord Genuity Group
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was upgraded by investment analysts at Canaccord Genuity Group to a 'hold' rating in a research report issued to clients and investors on Monday, Zacks reports. Can BioMarin Stock Live Up to Wall…
Ascendis Pharma A/S $ASND Stock: Nisa Investment Advisors LLC Increases Position
Nisa Investment Advisors LLC increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 28,468.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor…
Indian Stock Markets Unchanged: Crude Oil Prices, Bank Stocks, US Fed Policy Impact
Indian stock markets, including the Sensex and Nifty, concluded a volatile trading day largely unchanged, grappling with persistently high crude oil prices, significant selling in key bank stocks, and a cautious outlook ahead of the crucial US…
Cardiff Oncology Names Alland Interim Chief Medical Officer as Sidhu Steps Down
Cardiff Oncology said that Chief Medical Officer Roger Sidhu has stepped down. The company disclosed Sidhu's exit on Tuesday and appointed Leila Alland as interim chief medical officer. Alland previously was chief medical officer at companies…
AbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy) (NYSE:ABBV)
AbbVie Inc. is trading at all-time highs, with robust 2026 guidance and a market cap exceeding $500bn. I expect ABBV Q3 earnings to outperform, driven by immunology assets Skyrizi and Rinvoq, which together will generate over $30bn in 2026. Despite…
IQVIA (IQV) Q3 2026 Earnings Call Transcript
Senior Vice President, Investor Relations - Kerri Joseph Chairman and Chief Executive Officer - Ari Bousbib Executive Vice President and Chief Financial Officer - Michael J. Fedock Executive Vice President and General Counsel - Eric Sherbet Senior…
Nifty Prediction Today - October 27, 2026: Nifty futures: Breakout expected
Nifty 50 opened today's session lower at 22,709 versus Monday's close of 22,753. It is now trading at 22,730, down by a marginal 0.1 per cent. The advance/decline ratio of Nifty 50 now stands at 26/24. Tata Consumer Products (up 5.7 per cent) and…
Receive a Daily briefing on Pharma Industry News
Get Started